financetom
Business
financetom
/
Business
/
Ardelyx Insider Sold Shares Worth $342,983, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ardelyx Insider Sold Shares Worth $342,983, According to a Recent SEC Filing
Oct 2, 2024 10:37 PM

04:38 PM EDT, 10/01/2024 (MT Newswires) -- David P. Rosenbaum, Chief Development Officer, on September 27, 2024, sold 49,564 shares in Ardelyx ( ARDX ) for $342,983. Following the Form 4 filing with the SEC, Rosenbaum has control over a total of 533,154 shares of the company, with 301,946 shares held directly and 231,208 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1437402/000162828024041739/xslF345X05/wk-form4_1727814839.xml

Price: 6.82, Change: -0.03, Percent Change: -0.44

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Medpace Shares Fall After Q2 EPS, Revenue Increase, Updates Guidance
Update: Medpace Shares Fall After Q2 EPS, Revenue Increase, Updates Guidance
Jul 23, 2024
12:14 PM EDT, 07/23/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph.) Medpace ( MEDP ) shares were nearly 18% in recent trading on Tuesday, a day after the company reduced its 2024 revenue outlook. The company reported Q2 earnings late Monday of $2.75 per diluted share, up from $1.93 a year earlier. Analysts...
Merck Respiratory Syncytial Virus Treatment Study Meets Primary Endpoints
Merck Respiratory Syncytial Virus Treatment Study Meets Primary Endpoints
Jul 23, 2024
12:10 PM EDT, 07/23/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday that phase 2b/3 clinical trial evaluating clesrovimab in infant patients with respiratory syncytial virus disease, or RSV, met its primary safety and efficacy endpoints. The primary goal included reduced medically attended lower respiratory infections from RSV on day 150. The company will present detailed findings from the...
MSCI Q2 Earnings Impress Investors, CEO Emphasizes On Robust Client Base and Execution
MSCI Q2 Earnings Impress Investors, CEO Emphasizes On Robust Client Base and Execution
Jul 23, 2024
MSCI Inc ( MSCI ) reported fiscal 2024 second-quarter revenue growth of 14.0% year-on-year to $707.95 million, beating the analyst consensus estimate of $696.37 million.  The adjusted EPS of $3.64 beat the analyst consensus estimate of $3.55. The stock price gained after the results. The total run-rate at June 30, 2024, rose 14.6% Y/Y to $2.81 billion. The organic recurring subscription run rate growth was 8.6%. The retention...
LVMH sales grow 1% in second quarter, missing estimates
LVMH sales grow 1% in second quarter, missing estimates
Jul 23, 2024
PARIS, July 23 (Reuters) - LVMH, the world's biggest luxury company, posted a 1% rise in organic sales in the second quarter on Tuesday, missing analyst estimates, and likely adding to investor jitters about slowing growth in the sector. Sales at the French group, owner of labels Louis Vuitton, Tiffany & Co. and Hennessy, grew to 20.98 billion euros ($22.8...
Copyright 2023-2026 - www.financetom.com All Rights Reserved